Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich.
Pulmonary Division, University Hospital Zurich, Zurich; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Chest. 2013 Sep;144(3):746-749. doi: 10.1378/chest.13-1106.
Investigations on breath analysis have provided preliminary data on its potential in the noninvasive diagnosis of lung diseases. Although the conventional comparisons of exhaled breath in study populations (ie, diseased vs healthy) may help to identify patients with various lung diseases, we believe that the analysis of exhaled breath holds promise beyond this scenario. On the basis of preliminary findings, we hypothesize that breath analysis (1) could be applied not only to identify patients with lung disease but also to better phenotype healthy subjects at risk and patients with a particular disease, which is in-line with current efforts toward individualized medicine; (2) could be useful in estimating internal body time to determine the optimal time of drug administration, thereby maximizing drug activity and reducing toxicity (chronopharmacology); and (3) could be applied to monitor drugs or drug metabolites, thus, enhancing adherence to prescribed medications and enabling studies on pharmacokinetics.
对呼气分析的研究提供了其在非侵入性肺病诊断中的潜力的初步数据。虽然在研究人群中比较呼出的气体(即患病与健康)可能有助于识别各种肺病患者,但我们认为呼气分析的应用前景超出了这一范围。基于初步研究结果,我们假设呼气分析(1)不仅可以用于识别患有肺病的患者,还可以更好地表征处于危险中的健康受试者和患有特定疾病的患者,这符合当前个体化医学的努力;(2)可以用于估计体内时间,以确定最佳的给药时间,从而最大限度地提高药物活性和降低毒性(时间治疗学);(3)可用于监测药物或药物代谢物,从而提高对规定药物的依从性,并进行药代动力学研究。